Who are BD MDI 80 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone 125/formoterol 5, Fluticasone propionate/salmeterol combination, fluticasone/salmeterol in all asthmatics, Fluticasone 250/salmeterol 25, fluticasone and salmeterol, Fluticasone Propionate/Salmeterol Combination Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bd-mdi-80-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BD MDI 80 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BD MDI 80 µg (BD MDI 80 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 2 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

BD MDI 80 µg (BD MDI 80 µg) — Pearl Therapeutics, Inc.. BD MDI 80 µg is a budesonide/formoterol combination inhaler that reduces airway inflammation and improves bronchodilation for respiratory disease management.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BD MDI 80 µg TARGET	BD MDI 80 µg	Pearl Therapeutics, Inc.	phase 2	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Fluticasone 125/formoterol 5	Fluticasone 125/formoterol 5	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)
Fluticasone propionate/salmeterol combination	Fluticasone propionate/salmeterol combination	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone/salmeterol in all asthmatics	fluticasone/salmeterol in all asthmatics	Gelb, Arthur F., M.D.	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone 250/salmeterol 25	Fluticasone 250/salmeterol 25	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone and salmeterol	fluticasone and salmeterol	University of Chicago	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone Propionate/Salmeterol Combination Product	Fluticasone Propionate/Salmeterol Combination Product	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

GlaxoSmithKline · 14 drugs in this class
Pearl Therapeutics, Inc. · 5 drugs in this class
AstraZeneca · 4 drugs in this class
Research in Real-Life Ltd · 3 drugs in this class
Chiesi Farmaceutici S.p.A. · 2 drugs in this class
Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
Johns Hopkins University · 1 drug in this class
National Jewish Health · 1 drug in this class
SkyePharma AG · 1 drug in this class
University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BD MDI 80 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/bd-mdi-80-g. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing